Biotechnology company Maxion Therapeutics will become a new tenant of Suite 4 in The Works, located on Unity Campus, Cambridge.
The company is relocating from Babraham Research Campus to facilitate further growth. Maxion will occupy the 7,644 sq ft suite, a former home of Summit Therapeutics, which is relocating its research and development activities to the US.
The facility is fully fitted to CL2 laboratory standards and consists of two cell culture labs, an equipment room and two general purpose labs, as well as a wash-up and store area. There is also an office and write-up space, plus ancillary meeting rooms and a kitchenette.
John McCafferty, chief executive at Maxion, said: “Following our successful Series A fundraise earlier this year our team has rapidly grown, with the corresponding need for expanded facilities in the Cambridge area.”
Unity Campus is operated by regional property investor and developer Howard Group. Most recently, the campus saw Domainex, medicines research services firm, expand their space at the site.
Katherine Friend, director of investment and asset management at Howard, said: “Maxion joins an exciting and innovative Campus community which, in addition to undertaking ground-breaking research, also values the opportunity to interact and collaborate with each other outside the lab within the Campus ecosystem.”
Savills and JLL are joint agents for Unity Campus.
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
